January 2016

Teenagers with food allergies are more likely to suffer from depression, anxiety or attention-deficit hyperactivity disorder (ADHD), a new study reveals.

Text message reminders can help reduce people's blood pressure, according to a new joint study conducted by researchers at Britain's Oxford University and the University of Cape Town in South Africa.

Fifteen years ago when scientists the world over were still trying to understand the health benefit of the human stem-cell technology, an Indian specialist in the field took a step that left many in the scientific community bemused.

Having higher levels of Omega-3 fatty acids in your body can boost the impact of key vitamin B supplements, leading to slow mental decline in older people with memory problems, an international team has found.

By protecting the brain from shrinkage, aerobic exercise may slow the progression of Parkinsons disease, a progressive disorder of the nervous system, says a neurologist.In an editorial published online in the journal JAMA Neurology, neurologist J Eric Ahlskog from Mayo Clinic in Minnesota recommends that modern physical therapy practices should incorporate aerobic exercise training and encourage fitness for patients with Parkinson's disease.

Union Health Minister J.P. Nadda on Tuesday said there is a need for the Indian Council of Medical Research(ICMR) to endorse India's traditional medicinal system and boost research on the subject.

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring,  announced U.S. Food and Drug Administration approval for an expanded indication study of its most advanced transcatheter aortic heart valve, the Edwards SAPIEN 3 valve.  The investigational device exemption (IDE) study will enroll elderly patients with severe, symptomatic aortic stenosis (AS) who have been determined by a heart team to be at low risk for mortality if they were to undergo surgical aortic valve replacement.

MediciNova, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to MN-166 (ibudilast) for treatment of Type 1 - Early Infantile Krabbe disease.

The US Food and Drug Administration (FDA) issued a draft guidance outlining important steps medical device manufacturers should take to continually address cybersecurity risks to keep patients safe and better protect the public health.

Titan Pharmaceuticals, Inc.  and partner Braeburn Pharmaceuticals announced that the Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted 12 to 5 in favor of approving Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction, in stable patients receiving 8mg or less per day of buprenorphine. The Committee’s vote followed presentation and discussion of data regarding Probuphine’s efficacy, safety, and risk-benefit profile. The New Drug Application (NDA) for Probuphine was resubmitted to the FDA in August 2015, and accepted by the FDA in September 2015. A target agency action date has been set for February 27, 2016.